Paper Details

  1. Home
  2. Paper Details

Treatment of chronic hemodialysis patients with low-dose fenofibrate effectively reduces plasma lipids and affects plasma redox status.

Author: BaldEdward, ChwatkoGrażyna, DryjaPrzemysław, MakówkaAgnieszka, NowickiMichał

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dyslipidemia, a condition characterized by abnormal levels of fats in the blood, is common in patients on chronic hemodialysis. This study investigated the effects of low-dose fenofibrate, a medication used to lower triglycerides, on plasma lipids and oxidative stress in hemodialysis patients. Fenofibrate was found to effectively lower triglycerides and cholesterol while also improving antioxidant levels. These findings suggest that fenofibrate may be a safe and effective treatment option for dyslipidemia in hemodialysis patients.
Paper Details　
Original Abstract of the Article :
Dyslipidemia is common in chronic hemodialysis patients and its underlying mechanism is complex. Hemodialysis causes an imbalance between antioxidants and production of reactive oxygen species, which induces the oxidative stress and thereby may lead to accelerated atherosclerosis. Statins have been ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3390906/

データ提供：米国国立医学図書館（NLM）

Chronic Hemodialysis: Navigating the Desert of Dyslipidemia

The desert of chronic kidney disease is a harsh environment, with dyslipidemia often adding to the challenges faced by patients undergoing hemodialysis. This research delves into the potential benefits of low-dose fenofibrate therapy in managing dyslipidemia in this vulnerable population.

The authors meticulously designed a double-blind, placebo-controlled crossover study, examining the effects of low-dose fenofibrate on plasma lipids and redox status in chronic hemodialysis patients. They observed a significant decrease in total serum cholesterol, LDL cholesterol, and triglycerides, along with an increase in HDL cholesterol. Furthermore, the treatment positively influenced plasma aminothiol balance, shifting towards a more antioxidative pattern.

A New Oasis in the Desert of Kidney Disease: Fenofibrate Therapy for Dyslipidemia

This study provides a glimmer of hope in the desert of chronic kidney disease, suggesting that low-dose fenofibrate therapy could be a valuable tool for managing dyslipidemia in hemodialysis patients. The authors' findings highlight the potential for this medication to improve lipid profiles and potentially reduce the risk of cardiovascular complications.

Navigating the Desert of Cardiovascular Risk: A Holistic Approach to Hemodialysis

This research emphasizes the importance of a holistic approach to managing cardiovascular risk in hemodialysis patients. The authors' findings highlight the potential benefits of targeted lipid-lowering therapy in addition to other strategies aimed at improving cardiovascular health. This approach emphasizes the need for a comprehensive and individualized management plan for hemodialysis patients.

Dr. Camel's Conclusion

This study reminds us that even in the harsh desert of chronic kidney disease, there are oases of hope and innovation. The authors' exploration of low-dose fenofibrate therapy for dyslipidemia offers a valuable tool for managing cardiovascular risk in hemodialysis patients. Their research highlights the importance of a holistic approach to care, ensuring that patients receive the best possible support as they navigate the challenging desert of kidney disease.

Date :
  1. Date Completed 2012-12-20
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

22564753

DOI: Digital Object Identifier

PMC3390906

Related Literature

Article Analysis
・Side Effects of fenofibrate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.